体外受精のアジア市場

Inkwood Researchが発行した調査報告書(INKW807159)
◆英語タイトル:ASIA PACIFIC IN-VITRO FERTILIZATION MARKET FORECAST 2018-2026
◆商品コード:INKW807159
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2018年7月9日
◆ページ数:96
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アジア、日本、中国
◆産業分野:BIOTECHNOLOGY, HEALTHCARE
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Inkwood Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

KEY FINDINGSThe Asia-Pacific in-vitro fertilization (IVF) market is forecasted to rise with 12.68% CAGR over the estimated period of 2018-2026. The market is expected to hold much promise for the overall global IVF market, increasing its revenue from $xx million in 2017 to $xx million by the end of 2026.
MARKET INSIGHTS
The cost of IVF procedures is quite cheap in Asia-Pacific as compared to other regional markets. Hence the region is also being preferred by people all over the world for IVF treatments. Perhaps this is the reason that the Asia-Pacific IVF market is slated to showcase the highest CAGR increase for the forecast period as compared to other regional markets. Investments from private equity investors for further advancement in research and development in IVF techniques in this area are providing substantial growth opportunities for the market to grow. However, in some of these Asia-Pacific countries, male infertility is considered as a social taboo which refrains them from using the IVF methods. Instead, they prefer to go for traditional treatments to solve this problem. These factors could possibly restrict the growth of the Asia-Pacific market in the coming years.
COMPETITIVE INSIGHTS
Halotech DNA, Thermo Fisher Scientific Inc, Auxogyn, Copper Surgical Inc, Ovascience, Vitrolife Ab, Irvine Scientific (Subsidiary Of Nippon Mining Holdings), Cook Medical Inc, Genea, Merck Serono, Andrology Solutions, Esco Micro Pte. Ltd, Ferring Pharmaceuticals, and Ivftech Aps are some of the top companies engaged in this market.

【レポートの目次】

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ASIA PACIFIC SHOWS GREAT PROMISE FOR THE FORECAST PERIOD
3.2.2. INSURANCE COVERAGE FOR IVF
3.2.3. GROWTH OF MEDICAL TOURISM
4. MARKET DYNAMICS
4.1. MARKET DEFINITION
4.2. DRIVERS
4.2.1. INCREASING RATE OF INFERTILITY ACROSS THE GLOBE
4.2.2. FLEXIBLE GOVERNMENT REGULATIONS FOR FERTILITY TOURISM
4.2.3. IMPROVED SURROGACY LAWS
4.2.4. HIGH SUCCESS RATES OF ADVANCED IN-VITRO FERTILIZATION TREATMENTS
4.3. RESTRAINTS
4.3.1. HIGH COST
4.3.2. COUNTRY WISE REGULATORY ISSUES
4.4. OPPORTUNITIES
4.4.1. INCREASING DEMAND FOR LOW-COST PROCEDURES
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.5. CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO IVF
4.5.2.1. DIET AND SUPPLEMENTS
4.5.2.2. ACUPUNCTURE
4.5.2.3. THERAPY
4.5.2.4. QIGONG
5. MARKET BY PRODUCT AND PROCEDURES
5.1. BY PRODUCT
5.1.1. REAGENTS
5.1.2. EQUIPMENTS
5.2. BY PROCEDURE
5.2.1. INTRA CYTOPLASMIC SPERM INJECTION (ICSI)
5.2.2. PRE IMPLANTATION GENETIC DIAGNOSIS (PGD)
5.2.3. FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER)
5.2.4. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. KEY ANALYTICS
7.1. PORTERS 5 FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTE PRODUCTS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. INTENSITY OF COMPETITIVE RIVALRY
7.2. VALUE CHAIN ANALYSIS
7.2.1. RAW MATERIAL PROCUREMENT
7.2.2. MANUFACTURING
7.2.3. SUPPLY LOGISTICS
7.2.4. DISTRIBUTION CHANNELS
7.2.5. END USERS
7.3. KEY BUYING CRITERIA
7.3.1. TREATMENT OPTIONS
7.3.2. QUALITY OF MEDICAL PROCEDURES
7.3.3. PRICE OF TREATMENTS
7.3.4. SHIFT TOWARDS MEDICAL TOURISM
7.3.5. REIMBURSEMENT
7.4. REGULATORY FRAMEWORK
7.5. INVESTMENT OUTLOOK
7.5.1. END-USER OUTLOOK
7.6. VENDOR LANDSCAPE
7.7. OPPORTUNITY MATRIX
8. GEOGRAPHICAL ANALYSIS
8.1. CHINA
8.2. INDIA
8.3. JAPAN
8.4. AUSTRALIA
8.5. REST OF ASIA-PACIFIC
9. COMPETITIVE LANDSCAPE
9.1. MARKET SHARE ANALYSIS
9.1.1. VITROLIFE
9.1.2. COOPER SURGICAL
9.1.3. MERCK
9.1.4. COOK MEDICAL
9.1.5. FERRING PHARMACEUTICALS
9.2. TOP WINNING STRATEGIES
9.3. COMPANY PROFILES
9.3.1. ANDROLOGY SOLUTIONS
9.3.1.1. OVERVIEW
9.3.1.2. PRODUCT PORTFOLIO
9.3.1.3. SCOT ANALYSIS
9.3.1.4. STRATEGIC ANALYSIS
9.3.2. AUXOGYN
9.3.2.1. OVERVIEW
9.3.2.2. PRODUCTS
9.3.2.3. STRATEGIC INITIATIVES
9.3.2.4. SCOT ANALYSIS
9.3.2.5. STRATEGIC ANALYSIS
9.3.3. COOK MEDICAL INC
9.3.3.1. OVERVIEW
9.3.3.2. PRODUCT PORTFOLIO
9.3.3.3. STRATEGIC INITIATIVES
9.3.3.4. SCOT ANALY
9.3.3.5. STRATEGIC ANALYSIS
9.3.4. COPPER SURGICAL INC
9.3.4.1. OVERVIEW
9.3.4.2. PRODUCT PORTFOLIO
9.3.4.3. STRATEGIC INITIATIVES
9.3.4.4. SCOT ANALYSIS
9.3.4.5. STRATEGIC ANALYSIS
9.3.5. ESCO MICRO PTE. LTD.
9.3.5.1. OVERVIEW
9.3.5.2. PRODUCT PORTFOLIO
9.3.5.3. STRATEGIC INITIATIVES
9.3.5.4. SCOT ANALYSIS
9.3.5.5. STRATEGIC ANALYSIS
9.3.6. FERRING PHARMACEUTICALS
9.3.6.1. OVERVIEW
9.3.6.2. PRODUCT PORTFOLIO
9.3.6.3. STRATEGIC INITIATIVES
9.3.6.4. SCOT ANALYSIS
9.3.6.5. STRATEGIC ANALYSIS
9.3.7. GENEA
9.3.7.1. OVERVIEW
9.3.7.2. PRODUCT PORTFOLIO
9.3.7.3. STRATEGIC INITIATIVES
9.3.7.4. SCOT ANALYSIS
9.3.7.5. STRATEGIC ANALYSIS
9.3.8. HALOTECH DNA
9.3.8.1. OVERVIEW
9.3.8.2. PRODUCT PORTFOLIO
9.3.8.3. SCOT ANALYSIS
9.3.8.4. STRATEGIC ANALYSIS
9.3.9. IRVINE SCIENTIFIC (SUBSIDIARY OF NIPPON MINING HOLDINGS)
9.3.9.1. OVERVIEW
9.3.9.2. PRODUCT PORTFOLIO
9.3.9.3. STRATEGIC INITIATIVES
9.3.9.4. SCOT ANALYSIS
9.3.9.5. STRATEGIC ANALYSIS
9.3.10. IVFTECH APS
9.3.10.1. OVERVIEW
9.3.10.2. PRODUCT PORTFOLIO
9.3.10.3. SCOT ANALYSIS
9.3.10.4. STRATEGIC ANALYSIS
9.3.11. MERCK SERONO
9.3.11.1. OVERVIEW
9.3.11.2. PRODUCT PORTFOLIO
9.3.11.3. STRATEGIC INITIATIVES
9.3.11.4. SCOT ANALYSIS
9.3.11.5. STRATEGIC ANALYSIS
9.3.12. OVASCIENCE
9.3.12.1. OVERVIEW
9.3.12.2. PRODUCT PORTFOLIO
9.3.12.3. STRATEGIC INITIATIVES
9.3.12.4. SCOT ANALYSIS
9.3.12.5. STRATEGIC ANALYSIS
9.3.13. THE BAKER COMPANY, INC.
9.3.13.1. OVERVIEW
9.3.13.2. PRODUCT PORTFOLIO
9.3.13.3. SCOT ANALYSIS
9.3.13.4. STRATEGIC ANALYSIS
9.3.14. THERMO FISHER SCIENTIFIC INC
9.3.14.1. OVERVIEW
9.3.14.2. PRODUCT PORTFOLIO
9.3.14.3. STRATEGIC INITIATIVE
9.3.14.4. SCOT ANALYSIS
9.3.14.5. STRATEGIC ANALYSIS
9.3.15. VITROLIFE AB
9.3.15.1. OVERVIEW
9.3.15.2. PRODUCT PORTFOLIO
9.3.15.3. STRATEGIC INITIATIVES
9.3.15.4. SCOT ANALYSIS
9.3.15.5. STRATEGIC ANALYSIS
LIST OF TABLES
TABLE 1 ASIA PACIFIC IN-VITRO FERTILIZATION MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 2 ASIA PACIFIC IVF MARKET BY PRODUCT AND PROCEDURES 2018-2026 ($ MILLION)
TABLE 3 ASIA PACIFIC IVF MARKET BY PRODUCTS 2018-2026 ($ MILLION)
TABLE 4 ASIA PACIFIC IVF MARKET BY PROCEDURE 2018-2026 ($ MILLION)
TABLE 5 ASIA PACIFIC IVF MARKET BY END-USER 2018-2026 ($ MILLION)
TABLE 6 ASIA PACIFIC IVF MARKET BY COUNTRY 2018-2026 ($ MILLION)

LIST OF FIGURES
FIGURE 1 ASIA PACIFIC IN-VITRO FERTILIZATION MARKET BY PROCEDURE 2018-2026 ($ MILLION)
FIGURE 2 ASIA PACIFIC IVF MARKET 2018-2026 ($ MILLION)
FIGURE 3 EVOLUTION OF IVF MARKET
FIGURE 4 ASIA PACIFIC REAGENTS MARKET 2018-2026 ($ MILLION)
FIGURE 5 ASIA PACIFIC EQUIPMENTS MARKET 2018-2026 ($ MILLION)
FIGURE 6 ASIA PACIFIC INTRA CYTOPLASMIC SPERM INJECTION (ICSI) MARKET 2018-2026 ($ MILLION)
FIGURE 7 ASIA PACIFIC PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET 2018-2026 ($ MILLION)
FIGURE 8 ASIA PACIFIC FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET 2018-2026 ($ MILLION)
FIGURE 9 ASIA PACIFIC OTHERS MARKET 2018-2026 ($ MILLION)
FIGURE 10 ASIA PACIFIC FERTILITY AND SURGICAL CENTERS MARKET 2018-2026 ($ MILLION)
FIGURE 11 ASIA PACIFIC HOSPITALS AND RESEARCH LABORATORIES MARKET 2018-2026 ($ MILLION)
FIGURE 12 ASIA PACIFIC CRYOBANKS MARKET 2018-2026 ($ MILLION)
FIGURE 13 INVESTMENT PROPOSITION FOR ASIA PACIFIC IVF MARKET BY END-USER – 2017
FIGURE 14 CHINA IVF MARKET 2018-2026 ($ MILLION)
FIGURE 15 INDIA IVF MARKET 2018-2026 ($ MILLION)
FIGURE 16 JAPAN IVF MARKET 2018-2026 ($ MILLION)
FIGURE 17 AUSTRALIA IVF MARKET 2018-2026 ($ MILLION)
FIGURE 18 REST OF ASIA-PACIFIC IVF MARKET 2018-2026 ($ MILLION)
FIGURE 19 ASIA PACIFIC IVF MARKET SHARE OF MAJOR COMPANIES – 2017



【レポートのキーワード】

体外受精

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 体外受精のアジア市場(ASIA PACIFIC IN-VITRO FERTILIZATION MARKET FORECAST 2018-2026)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆